BACKGROUND: An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor (FGF) pathway activation has been proposed as a mechanism of escape from VEGF-targeted therapies. Dovitinib is an oral tyrosine-kinase inhibitor that inhibits VEGF and FGF receptors. We therefore compared dovitinib with sorafenib as third-line targeted therapies in patients with metastatic renal cell carcinoma. METHODS: In this multicentre phase 3 study, patients with clear cell metastatic renal cell carcinoma who received one previous VEGF-targeted therapy and one previous mTOR inhibitor were randomly assigned through an interactive voice and web response system to receive open-label dovitinib (500 mg orally according to a 5-days-on and 2-days-off schedule) or sorafenib (400 mg orally twice daily) in a 1:1 ratio. Randomisation was stratified by risk group and region. The primary endpoint was progression-free survival (PFS) assessed by masked central review. Efficacy was assessed in all patients who were randomly assigned and safety was assessed in patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01223027. FINDINGS: 284 patients were randomly assigned to the dovitinib group and 286 to the sorafenib group. Median follow-up was 11·3 months (IQR 7·9-14·6). Median PFS was 3·7 months (95% CI 3·5-3·9) in the dovitinib group and 3·6 months (3·5-3·7) in the sorafenib group (hazard ratio 0·86, 95% CI 0·72-1·04; one-sided p=0·063). 280 patients in the dovitinib group and 284 in the sorafenib group received at least one dose of study drug. Common grade 3 or 4 adverse events included hypertriglyceridaemia (38 [14%]), fatigue (28 [10%]), hypertension (22 [8%]), and diarrhoea (20 [7%]) in the dovitinib group, and hypertension (47 [17%]), fatigue (24 [8%]), dyspnoea (21 [7%]), and palmar-plantar erythrodysaesthesia (18 [6%]) in the sorafenib group. The most common serious adverse event was dyspnoea (16 [6%] and 15 [5%] in the dovitinib and sorafenib groups, respectively). INTERPRETATION: Dovitinib showed activity, but this was no better than that of sorafenib in patients with renal cell carcinoma who had progressed on previous VEGF-targeted therapies and mTOR inhibitors. This trial provides reference outcome data for future studies of targeted inhibitors in the third-line setting. FUNDING: Novartis Pharmaceuticals Corporation.

Asan Medical Center Seoul South Korea

BC Cancer Agency Vancouver Cancer Centre Vancouver BC Canada

Comprehensive Cancer Centers of Nevada Las Vegas NV USA

Hanover Medical School Hanover Germany

Hospital Universitario Central de Asturias Oviedo Asturias Spain

Institut Gustave Roussy Villejuif France

IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Meldola Italy

Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation Pavia Italy

Maria Sklodowska Curie Institute Warsaw Poland

Memorial Sloan Kettering Cancer Center New York NY USA

Military Institute of Health Services in Warsaw Warsaw Poland

Monash University Eastern Health Clinical School Melbourne VIC Australia

Novartis Pharma Basel Switzerland

Novartis Pharmaceuticals Corporation East Hanover NJ USA

Palacký University Medical School and Teaching Hospital Olomouc Czech Republic

San Camillo and Forlanini Hospitals Rome Italy

Sunnybrook Odette Cancer Centre Toronto ON Canada

Yonsei Cancer Center Yonsei University College of Medicine Seoul South Korea

Lancet Oncol. 2014 Mar;15(3):245-6. doi: 10.1016/S1470-2045(14)70082-8. PubMed

Nat Rev Urol. 2014 Apr;11(4):186. doi: 10.1038/nrurol.2014.55. PubMed

Zobrazit více v PubMed

Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol. 2012;9:327–37. PubMed

Bukowski RM. Temsirolimus: a safety and efficacy review. Expert Opin Drug Saf. 2012;11:861–79. PubMed

National Comprehensive Cancer Network. Clinical practice guidelines in oncology. [accessed December 10, 2013];Kidney cancer version 2.2014. 2013 http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.

European Association of Urology. Ljungberg B, Bensalah K, Bex A, et al. [accessed May 7, 2013];Guidelines on renal cell carcinoma. 2013 http://www.uroweb.org/gls/pdf/10_Renal_Cell_Carcinoma_LRV2.pdf.

Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159–78. PubMed

Granato AM, Nanni O, Falcini F, et al. Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools? Breast Cancer Res. 2004;6:R38–45. PubMed PMC

Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets. 2009;9:639–51. PubMed PMC

Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8:299–309. PubMed

Tsimafeyeu I, Demidov H, Ta H, Stepanova E, Wynn N. Fibroblast growth factor pathway in renal cell carcinoma. J Clin Oncol. 2010;28(suppl) abstr 4621. PubMed

Porta C, Paglino C, Imarisio I, et al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology. 2013;84:115–22. PubMed

Lee SH, Lopes de Menezes D, Vora J, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res. 2005;11:3633–41. PubMed

Angevin E, Lopez-Martin J, Lin CC, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013;19:1257–68. PubMed

Sivanand S, Peña-Llopis S, Zhao H, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med. 2012;4:137ra75. PubMed PMC

Angevin E, Grünwald V, Ravaud A, et al. A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC) J Clin Oncol. 2011;29(suppl) abstr 4551.

Garcia JA, Hutson TE, Elson P, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer. 2010;116:5383–90. PubMed

Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9. PubMed

Di Lorenzo G, Buonerba C, Federico P, et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol. 2010;58:906–11. PubMed

Di Lorenzo G, Carteni G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 2009;27:4469–74. PubMed

Hutson T, Escudier B, Esteban E, et al. Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial. Ann Oncol. 2012;23(suppl 9) abstr LBA22.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–47. PubMed

Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–63. PubMed

Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56. PubMed

Wang X, Kay A, Anak O, et al. Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib. J Clin Pharmacol. 2013;53:14–20. PubMed

Calvo E, Escudier B, Motzer RJ, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer. 2012;48:333–9. PubMed

Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM. Phase I/II and pharmacodynamic study of dovitinib (TKI258)—an inhibitor of fibroblast growth factor receptors and VEGF receptors—in patients with advanced melanoma. Clin Cancer Res. 2011;17:7451–61. PubMed

Björnsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther. 2006;79:521–8. PubMed

US Food and Drug Administration. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. 2009

Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry

Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01223027